Suchergebnisse - "Siefker-Radtke, A O"

PubPharm (11)

1

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations : cohort 2 of the randomized phase III THOR trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2024

von Siefker-Radtke, A. | Matsubara, N. | Park, S. | +113

2

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Feils, A. | Erbe, A. | Birstler, J. | +10

3

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial

enthalten in: Cancer immunology immunotherapy | 2023

von Feils, A. | Erbe, A. | Birstler, J. | +10

4

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial

enthalten in: Cancer immunology immunotherapy | 2023

von Feils, A. | Erbe, A. | Birstler, J. | +10

5

Upper tract urothelial carcinoma topical issue 2016 : treatment of metastatic cancer

enthalten in: World journal of urology | 2017

von Pham, M. | Apolo, A. | De Santis, M. | +11

6

Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer

enthalten in: World journal of urology | 2016

von Pham, M. | Apolo, A. | De Santis, M. | +11

7

Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer

enthalten in: World journal of urology | 2016

von Pham, M. | Apolo, A. | De Santis, M. | +11

8

Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer

enthalten in: World journal of urology | 2016

von Pham, M. | Apolo, A. | De Santis, M. | +11

9

National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer

enthalten in: Journal of clinical oncology / Englische Ausgabe | 2016

von Pal, S. | Agarwal, N. | Boorjian, S. | +4

10

Ongoing phase 2 study of erdafitinib (JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (M/UR UC) and FGFR gene alterations

enthalten in: Annals of oncology | 2016

von Siefker-Radtke, A. | Mellado, B. | Decaestecker, K. | +8